Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of CMB305 in NY-ESO-1 Positive Synovial Sarcoma After First-line Therapy
2018-000824-32Phase 3Terminated
- Sponsor
- Immune Design
- Start
- Jul 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in synovial sarcoma (SS) comparing CMB305 Arm with Placebo Arm (2 arms). Started Jul 2018; status: terminated.
02
Drugs
CMB305
03
Conditions
synovial sarcoma (SS)
Beyond the preview
Go deeper on 2018-000824-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000824-32.